- Home
- ADAP vs MCHX Comparison
ADAP vs MCHX Comparison
Compare ADAP & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- MCHX
- Stock Information
- Founded
- ADAP 2008
- MCHX 2003
- Country
- ADAP United Kingdom
- MCHX United States
- Employees
- ADAP N/A
- MCHX N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- MCHX Business Services
- Sector
- ADAP Health Care
- MCHX Consumer Discretionary
- Exchange
- ADAP Nasdaq
- MCHX Nasdaq
- Market Cap
- ADAP 71.6M
- MCHX 84.3M
- IPO Year
- ADAP 2015
- MCHX 2004
- Fundamental
- Price
- ADAP $0.21
- MCHX $1.68
- Analyst Decision
- ADAP Strong Buy
- MCHX
- Analyst Count
- ADAP 5
- MCHX 0
- Target Price
- ADAP $1.93
- MCHX N/A
- AVG Volume (30 Days)
- ADAP 2.4M
- MCHX 56.7K
- Earning Date
- ADAP 03-20-2025
- MCHX 03-06-2025
- Dividend Yield
- ADAP N/A
- MCHX N/A
- EPS Growth
- ADAP N/A
- MCHX N/A
- EPS
- ADAP N/A
- MCHX N/A
- Revenue
- ADAP $178,032,000.00
- MCHX $48,122,000.00
- Revenue This Year
- ADAP N/A
- MCHX $6.93
- Revenue Next Year
- ADAP $56.87
- MCHX $7.04
- P/E Ratio
- ADAP N/A
- MCHX N/A
- Revenue Growth
- ADAP 195.34
- MCHX N/A
- 52 Week Low
- ADAP $0.20
- MCHX $1.20
- 52 Week High
- ADAP $1.55
- MCHX $2.40
- Technical
- Relative Strength Index (RSI)
- ADAP 14.09
- MCHX 33.05
- Support Level
- ADAP $0.26
- MCHX $1.68
- Resistance Level
- ADAP $0.47
- MCHX $1.99
- Average True Range (ATR)
- ADAP 0.04
- MCHX 0.11
- MACD
- ADAP -0.02
- MCHX -0.03
- Stochastic Oscillator
- ADAP 1.23
- MCHX 6.82
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
About MCHX Marchex Inc. Class B
Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.